NPI: 1508269200 · LOUISVILLE, KY 40299 · Physical Therapist · NPI assigned 10/08/2014
Authorized official CLAY, DANYEL controls 20+ related entities in our dataset. Read more
| Authorized Official | CLAY, DANYEL (VICE PRESIDEDNT, REVENUE CYCLE) |
| NPI Enumeration Date | 10/08/2014 |
Other providers sharing the same authorized official: CLAY, DANYEL
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 76,756 | $2.47M |
| 2019 | 98,007 | $2.99M |
| 2020 | 84,581 | $2.43M |
| 2021 | 135,876 | $3.92M |
| 2022 | 184,023 | $5.52M |
| 2023 | 176,539 | $5.28M |
| 2024 | 131,211 | $3.97M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 300,024 | 276,557 | $9.76M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 83,121 | 77,818 | $4.15M |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 42,521 | 38,480 | $2.38M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 69,021 | 58,581 | $1.68M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 70,270 | 27,320 | $1.53M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 95,292 | 89,845 | $1.30M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 31,535 | 10,420 | $1.07M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 33,880 | 13,207 | $1.05M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 41,459 | 39,447 | $986K |
| 87428 | 29,091 | 27,540 | $844K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 28,891 | 12,038 | $503K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 17,549 | 6,887 | $352K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3,841 | 3,439 | $141K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1,659 | 1,517 | $135K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5,742 | 5,288 | $134K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 9,793 | 8,723 | $128K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,232 | 1,137 | $79K |
| 97162 | 1,159 | 1,022 | $48K | |
| 87807 | 3,430 | 3,327 | $41K | |
| 92609 | 625 | 230 | $35K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1,228 | 1,153 | $31K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 510 | 466 | $31K |
| 97535 | Self-care/home management training, each 15 minutes | 1,236 | 704 | $20K |
| 71046 | Radiologic examination, chest; 2 views | 1,393 | 1,317 | $16K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 394 | 362 | $15K |
| 81025 | 2,143 | 1,954 | $13K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 109 | 103 | $13K |
| 97014 | 1,985 | 897 | $13K | |
| 97161 | 294 | 283 | $12K | |
| 97533 | 434 | 180 | $12K | |
| 97113 | 188 | 81 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 714 | 623 | $6K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 588 | 549 | $5K |
| 92523 | 44 | 33 | $4K | |
| 99422 | 262 | 242 | $4K | |
| 97116 | 233 | 119 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 348 | 315 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 354 | 286 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 20 | 15 | $2K |
| 99201 | 71 | 63 | $2K | |
| 97035 | 224 | 106 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 939 | 863 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 152 | 135 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 161 | 132 | $1K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 138 | 127 | $902.62 |
| 87400 | 84 | 48 | $735.14 | |
| 97166 | 13 | 13 | $712.30 | |
| 81003 | 1,294 | 1,043 | $672.94 | |
| 73630 | 73 | 65 | $573.22 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 234 | 216 | $539.97 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 176 | 76 | $392.70 |
| 73610 | 32 | 30 | $345.97 | |
| 97032 | 38 | 26 | $236.89 | |
| 99406 | 14 | 13 | $111.82 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 14 | 12 | $108.21 |
| 99421 | 16 | 14 | $105.76 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 12 | 12 | $70.38 |
| 86308 | 14 | 13 | $62.31 | |
| 90633 | 370 | 316 | $47.95 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 92 | 73 | $23.10 |
| 90734 | 75 | 74 | $18.40 | |
| 36415 | Collection of venous blood by venipuncture | 42 | 38 | $12.68 |
| 90686 | 60 | 59 | $0.00 | |
| 90715 | 15 | 15 | $0.00 | |
| 99001 | 28 | 27 | $0.00 |